<DOC>
	<DOC>NCT00666406</DOC>
	<brief_summary>The purpose of this study is to compare the pharmacokinetic parameters and safety of Advate rAHF-PFM versus Recombinate rAHF in well described previously treated patients with severe hemophilia A (factor VIII level &lt; 1%).</brief_summary>
	<brief_title>Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Signed informed consent obtained from participant or legally authorized representative 1560 years old Factor VIII level &lt; 1% as documented by previously measured factor VIII and genotyping Previously treated with factor VIII concentrate(s) for a minimum of at least 150 exposure days (as documented by the study site investigator) prior to study entry Observed decrease of efficacy by subject and/or treating physician after being switched from Recombinate rAHF to Advate rAHFPFM The participant has a detectable factor VIII inhibitor at screening, with a titer &gt;= 0.4 Bethesda Unit (BU) (Nijmegen modification of the Bethesda Assay) measured at the local and the central laboratory The participant has a known hypersensitivity to mouse or hamster proteins The participant is participating in another investigational drug study within 30 days prior to screening The participant is identified by the investigator as being unable or unwilling to cooperate with study procedures</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>